Recent Posts
- New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations
- Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024
- European Society For Medical Oncology (ESMO)
- H.C. Wainwright 27th Annual Global Investment Conference
- ImmunityBio’s ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy